CSF2 and melanoma: For all three situations, Imlygic was compared by the manufacturer against the granulocyte-macrophage colony-stimulating factor (GM-CSF), which did not concur with the comparator specified by the G-BA for any of the research questions, and is also not approved for the treatment of melanoma.